**QIBA SPECT Biomarker Committee (BC)**
**Friday, January 22, 2016, 9 AM (CT)**
Draft Call Summary

**In attendance:**

| | | | |
|---|---|---|---|
| *Yuni Dewaraja, PhD (Co-Chair)* | John Dickson, PhD | Eric Perlman , MD | **RSNA** |
| *P. David Mozley, MD (Co-Chair)* | Paul Kinahan, PhD | Pierre Tervé, MS | Joe Koudelik |
| *John Seibyl, MD (Co-Chair)* | Robert Miyaoka, PhD | Brian Zimmerman, PhD | Julie Lisiecki |
| Patrick Cella, MSc | Nancy Obuchowski, PhD | | |

**Moderator:** Dr. Seibyl

**QIBA SPECT BC Draft Profile (Dr. Seibyl):**

- A draft version of the SPECT Biomarker Committee Profile is in preparation for discussion on the February 19th BC call
- The current draft will be distributed and wiki-posted for additions, comments, and edits prior to this next call
    - Current working title is:
        - "Quantifying Dopamine Transporters with123-Iodine Labeled Ioflupane in Neurodegenerative Disease"
    - Shorter title is:
        - "QIBA Draft Profile: SPECT Dopamine Transporters"

- **Sections have been assigned to primary authors as follows**:

| | | | |
|---|---|---|---|
| o | Executive Summary | | Mozley/Seibyl/whole committee |
| o | 3.1-3.2 | (Pre-delivery, Installation) | Device manufacturers/Cella |
| o | 3.3 | (Periodic QA) | Dickson/Zimmerman, et al. |
| o | 3.4 -3.5 | (Subject selection / handling) | Mozley/Seibyl |
| o | 3.6 | (Acquisition) | Dewaraja |
| o | 3.7 | (Reconstruction) | Frey/Dewaraja |
| o | 3.8 | (Image QA) | Dickson/Zimmerman |
| o | 3.9 | (Image Distribution) | Klein/ Tervé |
| o | 3.10 | (Image Analysis) | Miyaoka/Seibyl |
| o | 3.11 | (Image Interpretation) | Seibyl, et al. |
| o | Section 2 | | Obuchowski / Anne Smith |

- Writing technique of "spiraling in" was recommended to get a completed Profile draft for more detailed editing later
    - The technique is explained as follows (per Dr. Mozley):
        - Write fast. Leave nothing blank. Use PET data when it's handier than SPECT data. Use Technetium data if you find it before I-123 data.
        - Highlight in yellow all scalar values that are not sound for this use case.
        - Make comments in tracked changes mode about passages for which there is
            - No consensus
            - Unacceptable uncertainty
            - Known controversy
            - The information comes from another use case, e.g., PET
            - The information has been made up, i.e., fabricated out of thin air, etc.
- Development of a separate UPICT protocol was deemed unnecessary since this detail would integrate within Section 3 of the Profile
- A project tracking chart was set up to show estimated timelines and status of work at-a-glance
- The group also discussed what may be needed in terms of support for the claims and methodology such as:
    - additional studies
    - phantoms
    - projects
- Any proposed projects should be considered if proposals could be submitted for the next round of funding from QIBA
- (See Dr. Seibyl's presentation slides for additional details.)

**Action item:** Profile section authors to complete a rough draft prior to the next meeting of the BC on Friday, Feb. 19th

---

**Nuclear Medicine BC Calls:**

- Feb 05: FDG-PET BC
- Feb 12: Amyloid BC
- Feb 19: SPECT BC
- Feb 26: Combined NM BCs

**SPECT Task Forces: (Tuesdays at 2 pm CT)** – *pending availability of co-chairs*

- Feb 02: Image Acquisition and Image Processing for DaTscan – *Dr. Dewaraja*
- Feb 09: Quantitative / Image Analysis – *Drs. Miyaoka and Seibyl*
- Feb 16: Phantoms / DRO Group – *Drs. Dickson and Zimmerman*
- Feb 23: Clinical / Literature Review – *Dr. Seibyl*

---

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries. QIBA wiki